Area of research
Immunology · Virology
Research interest
Research interests include HIV Research and Treatment, SARS-CoV-2 and COVID-19 Research, Influenza Virus Research Studies, and Immunotherapy and Immune Responses.
Vaccination with mRNA-encoded nanoparticles drives early maturation of HIV bnAb precursors in humans
Precise targeting of HIV broadly neutralizing antibody precursors in humans
Virologic effects of broadly neutralizing antibodies VRC01LS and VRC07-523LS on chronic HIV-1 infection
Dynamics of endemic virus re-emergence in children in the USA following the COVID-19 pandemic (2022–23): a prospective, multicentre, longitudinal, immunoepidemiological surveillance study
Human immunoglobulin gene allelic variation impacts germline-targeting vaccine priming
Germline-targeting HIV vaccination induces neutralizing antibodies to the CD4 binding site
Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIV
Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trial
Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127/HPTN 087): A Phase I randomized clinical trial
Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial
Broadly neutralizing antibody treatment maintained HIV suppression in children with favorable reservoir characteristics in Botswana
Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trial
Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trial
Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition
Soluble prefusion-closed HIV-envelope trimers with glycan-covered bases
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
Homologous and Heterologous Covid-19 Booster Vaccinations
Vaccination induces HIV broadly neutralizing antibody precursors in humans
mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron
Defining the risk of SARS-CoV-2 variants on immune protection
Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria
Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial
Co-immunization with hemagglutinin stem immunogens elicits cross-group neutralizing antibodies and broad protection against influenza A viruses
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants
Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates
mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates
<i>Plasmodium falciparum</i> –specific IgM B cells dominate in children, expand with malaria, and produce functional IgM
Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials
Rectal tissue and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challenge